A PYMNTS Company

US: Allergan-KYTHERA deal gets approval

By  |  July 28, 2015

Allergan and KYTHERA Biopharmaceuticals announced that the US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The early termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions, including receipt of approval by KYTHERA’s stockholders.

    Full content: The Wall Street Transcript

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.